Mark Goodwin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mark Goodwin has a total of 188 co-authors. Here are the top co-authors by number of shared publications:
- Antoine Guillaume Schneider
Adult Intensive Care Unit, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
5 shared publications - Rinaldo Bellomo
Department of Intensive Care, Austin Hospital, Melbourne, VIC, Australia
5 shared publications - Numan Kutaiba
Department of Radiology, Austin Health, Melbourne, VIC 3084, Australia
4 shared publications - Anthony Schelleman
Radiology department, Austin Health, Heidelberg, VIC, Australia
3 shared publications - Lynne Johnson
Radiology department, Austin Health, Heidelberg, VIC, Australia
3 shared publications - Michael Bailey
Australian and New Zealand Intensive Care Research Centre, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
3 shared publications
Latest Publications
- 11 November 2026
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
Validation of the MAAPE Score for Predicting Clinical Outcomes in Hepatocellular Carcinoma Treated With Selective Internal Radiation Therapy
Background: Selective internal radiation therapy (SIRT) is an established treatment option for hepatocellular carcinoma (HCC); however, patient selection remains challenging. The MAAPE score (MELD, Albumin, AFP, PVTT, ECOG) was recently developed as a prognostic tool. This study aimed to provide an independent, single‐centre external validation of the MAAPE score in predicting clinical outcomes for patients treated with Yttrium‐90 SIRT. Methods: A retrospective analysis of patients with HCC treated with SIRT at a tertiary centre in Australia between 2012 and 2024 was performed. All patients received SIRT as first‐line treatment. Patients were stratified into Good, Average, and Poor prognosis groups based on their pre‐treatment MAAPE score. Tumour response and survival outcomes at 12 months were assessed as endpoints. Statistical analysis was performed using Kendall's rank correlation, Mann–Whitney tests, and Fisher's exact tests. Results: A total of 64 patients were included, of whom 62 were evaluable for 12‐month survival. Patients were stratified into Good ( n = 18; 28.1%), Average ( n = 29; 45.3%), and Poor ( n = 17; 26.6%) prognosis groups. The MAAPE score demonstrated a significant correlation with 12‐month survival ( p = 0.008) and tumour response ( p = 0.030). Patients in the Good prognosis group achieved an 88.2% survival rate at 12 months, compared to 62.1% and 43.8% for the Average and Poor groups respectively. While correlations were statistically significant, pairwise comparisons between prognosis groups were only significant when comparing Good and Poor ( p = 0.010 for 12‐month survival and p = 0.046 for tumour response). Conclusion: In this small single‐centre cohort, the MAAPE score identified patients with the most and least favourable 12‐month outcomes. It did not separate the adjacent prognosis groups from each other. These findings support the score at the extremes of risk, but they are preliminary. Larger prospective multicentre studies are required to assess the value of this score in personalised patient management.
- 11 November 2026
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
Validation of the MAAPE Score for Predicting Clinical Outcomes in Hepatocellular Carcinoma Treated With Selective Internal Radiation Therapy
Background: Selective internal radiation therapy (SIRT) is an established treatment option for hepatocellular carcinoma (HCC); however, patient selection remains challenging. The MAAPE score (MELD, Albumin, AFP, PVTT, ECOG) was recently developed as a prognostic tool. This study aimed to provide an independent, single‐centre external validation of the MAAPE score in predicting clinical outcomes for patients treated with Yttrium‐90 SIRT. Methods: A retrospective analysis of patients with HCC treated with SIRT at a tertiary centre in Australia between 2012 and 2024 was performed. All patients received SIRT as first‐line treatment. Patients were stratified into Good, Average, and Poor prognosis groups based on their pre‐treatment MAAPE score. Tumour response and survival outcomes at 12 months were assessed as endpoints. Statistical analysis was performed using Kendall's rank correlation, Mann–Whitney tests, and Fisher's exact tests. Results: A total of 64 patients were included, of whom 62 were evaluable for 12‐month survival. Patients were stratified into Good ( n = 18; 28.1%), Average ( n = 29; 45.3%), and Poor ( n = 17; 26.6%) prognosis groups. The MAAPE score demonstrated a significant correlation with 12‐month survival ( p = 0.008) and tumour response ( p = 0.030). Patients in the Good prognosis group achieved an 88.2% survival rate at 12 months, compared to 62.1% and 43.8% for the Average and Poor groups respectively. While correlations were statistically significant, pairwise comparisons between prognosis groups were only significant when comparing Good and Poor ( p = 0.010 for 12‐month survival and p = 0.046 for tumour response). Conclusion: In this small single‐centre cohort, the MAAPE score identified patients with the most and least favourable 12‐month outcomes. It did not separate the adjacent prognosis groups from each other. These findings support the score at the extremes of risk, but they are preliminary. Larger prospective multicentre studies are required to assess the value of this score in personalised patient management.
- Open Access
Prognostic Value and Inter-Reader Agreement of the ANALING and DiStrict MRCP Scores in Primary Sclerosing Cholangitis
Background/Objectives: The ANALI and DiStrict scores are novel quantitative magnetic resonance cholangio-pancreatography (MRCP)-derived scoring systems designed to predict outcomes in primary sclerosing cholangitis (PSC). However, as their prognostic utility and inter-reader reproducibility are not widely validated, their utility in clinical practice is currently limited. This study aimed to assess the reproducibility and prognostic performance of the ANALI without gadolinium (ANALING) and DiStrict scores in predicting liver-related outcomes in patients with PSC. Methods: We conducted a multicentre retrospective cohort study enrolling adult patients with large-duct PSC and at least one MRCP from the time of diagnosis. MRCPs were scored by five blinded senior abdominal radiologists with inter- and intra-reader agreement assessed via intraclass correlation coefficients. Multivariate Cox proportional models were used to evaluate the prognostic value of the ANALING and DiStrict scores, with a composite endpoint of liver transplantation, hepatic decompensation, or liver-related death. Results: Eighty-nine patients with a median of 5.5 years (IQR 3.4–9.2) of follow-up were included. The ANALING score showed higher intra-reader agreement (ICC 0.87, 95% CI 0.82–0.92 vs. ICC 0.64, 95% CI 0.36–0.79) and similar inter-reader agreement (ICC 0.71, 95% CI 0.63–0.78 vs. ICC 0.67, 95% CI 0.59–0.75) compared to the DiStrict score. Only the ANALING score was associated with liver-related events, which remained significant when adjusted for age and sex (aHR 1.28, 95% CI 1.01–1.63) and MELD (aHR 1.69, 95% CI 1.22–2.34). Conclusions: The ANALING score is a reproducible, MRI-derived scoring system that is independently associated with liver outcomes and has higher intra-reader agreement compared to the DiStrict score.
Open AccessPrognostic Value and Inter-Reader Agreement of the ANALING and DiStrict MRCP Scores in Primary Sclerosing Cholangitis
Background/Objectives: The ANALI and DiStrict scores are novel quantitative magnetic resonance cholangio-pancreatography (MRCP)-derived scoring systems designed to predict outcomes in primary sclerosing cholangitis (PSC). However, as their prognostic utility and inter-reader reproducibility are not widely validated, their utility in clinical practice is currently limited. This study aimed to assess the reproducibility and prognostic performance of the ANALI without gadolinium (ANALING) and DiStrict scores in predicting liver-related outcomes in patients with PSC. Methods: We conducted a multicentre retrospective cohort study enrolling adult patients with large-duct PSC and at least one MRCP from the time of diagnosis. MRCPs were scored by five blinded senior abdominal radiologists with inter- and intra-reader agreement assessed via intraclass correlation coefficients. Multivariate Cox proportional models were used to evaluate the prognostic value of the ANALING and DiStrict scores, with a composite endpoint of liver transplantation, hepatic decompensation, or liver-related death. Results: Eighty-nine patients with a median of 5.5 years (IQR 3.4–9.2) of follow-up were included. The ANALING score showed higher intra-reader agreement (ICC 0.87, 95% CI 0.82–0.92 vs. ICC 0.64, 95% CI 0.36–0.79) and similar inter-reader agreement (ICC 0.71, 95% CI 0.63–0.78 vs. ICC 0.67, 95% CI 0.59–0.75) compared to the DiStrict score. Only the ANALING score was associated with liver-related events, which remained significant when adjusted for age and sex (aHR 1.28, 95% CI 1.01–1.63) and MELD (aHR 1.69, 95% CI 1.22–2.34). Conclusions: The ANALING score is a reproducible, MRI-derived scoring system that is independently associated with liver outcomes and has higher intra-reader agreement compared to the DiStrict score.
- 6 February 2024
- Published by BMJ in BMJ Case Reports
- Vol. 17 (2) , e256710
Small bowel obstruction caused by dehydrated apple ingestion: the challenges of preoperative radiological diagnosis and surgical management
A man in his 60s with a virgin abdomen presented with sudden-onset generalised abdominal pain and fevers. The night prior, he snacked on supermarket purchased dehydrated apples. CT abdomen and pelvis revealed small bowel obstruction (SBO) to the mid ileum and small amount of free fluid within the pelvis. The patient underwent emergency exploratory laparotomy. High-grade SBO was identified, caused by large obstructing phytobezoars, with three further proximal large phytobezoars identified. All four phytobezoars were extracted and found to be rehydrated pieces of dehydrated apple that had increased in size in the gastrointestinal tract. The patient was later found to have further phytobezoars in the stomach which passed conservatively. The patient recovered well. This case demonstrates the challenges of preoperative radiological diagnosis in phytobezoar-related SBO and the significance of enterotomy orientation and closure to ensure a safe repair to withstand the passage of any residual rehydrating phytobezoars.
- 6 February 2024
- Published by BMJ in BMJ Case Reports
- Vol. 17 (2) , e256710
Small bowel obstruction caused by dehydrated apple ingestion: the challenges of preoperative radiological diagnosis and surgical management
A man in his 60s with a virgin abdomen presented with sudden-onset generalised abdominal pain and fevers. The night prior, he snacked on supermarket purchased dehydrated apples. CT abdomen and pelvis revealed small bowel obstruction (SBO) to the mid ileum and small amount of free fluid within the pelvis. The patient underwent emergency exploratory laparotomy. High-grade SBO was identified, caused by large obstructing phytobezoars, with three further proximal large phytobezoars identified. All four phytobezoars were extracted and found to be rehydrated pieces of dehydrated apple that had increased in size in the gastrointestinal tract. The patient was later found to have further phytobezoars in the stomach which passed conservatively. The patient recovered well. This case demonstrates the challenges of preoperative radiological diagnosis in phytobezoar-related SBO and the significance of enterotomy orientation and closure to ensure a safe repair to withstand the passage of any residual rehydrating phytobezoars.
- Open Access
- 27 October 2023
- Published by Elsevier in Mayo Clinic Proceedings: Digital Health
- Vol. 1 (4) , 574-585
Deep Learning for Computed Tomography Assessment of Hepatic Fibrosis and Cirrhosis: A Systematic Review
- 27 October 2023
- Published by Elsevier in Mayo Clinic Proceedings: Digital Health
- Vol. 1 (4) , 574-585
Open AccessDeep Learning for Computed Tomography Assessment of Hepatic Fibrosis and Cirrhosis: A Systematic Review
- Open Access
Determination of “borderline resectable” pancreatic cancer – A global assessment of 30 shades of grey
- 1 June 2023
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 307 (5) , e222855
A Multicenter Assessment of Interreader Reliability of LI-RADS Version 2018 for MRI and CT
Background Various limitations have impacted research evaluating reader agreement for Liver Imaging Reporting and Data System (LI-RADS). Purpose To assess reader agreement of LI-RADS in an international multicenter multireader setting using scrollable images. Materials and Methods This retrospective study used deidentified clinical multiphase CT and MRI and reports with at least one untreated observation from six institutions and three countries; only qualifying examinations were submitted. Examination dates were October 2017 to August 2018 at the coordinating center. One untreated observation per examination was randomly selected using observation identifiers, and its clinically assigned features were extracted from the report. The corresponding LI-RADS version 2018 category was computed as a rescored clinical read. Each examination was randomly assigned to two of 43 research readers who independently scored the observation. Agreement for an ordinal modified four-category LI-RADS scale (LR-1, definitely benign; LR-2, probably benign; LR-3, intermediate probability of malignancy; LR-4, probably hepatocellular carcinoma [HCC]; LR-5, definitely HCC; LR-M, probably malignant but not HCC specific; and LR-TIV, tumor in vein) was computed using intraclass correlation coefficients (ICCs). Agreement was also computed for dichotomized malignancy (LR-4, LR-5, LR-M, and LR-TIV), LR-5, and LR-M. Agreement was compared between research-versus-research reads and research-versus-clinical reads. Results The study population consisted of 484 patients (mean age, 62 years ± 10 [SD]; 156 women; 93 CT examinations, 391 MRI examinations). ICCs for ordinal LI-RADS, dichotomized malignancy, LR-5, and LR-M were 0.68 (95% CI: 0.61, 0.73), 0.63 (95% CI: 0.55, 0.70), 0.58 (95% CI: 0.50, 0.66), and 0.46 (95% CI: 0.31, 0.61) respectively. Research-versus-research reader agreement was higher than research-versus-clinical agreement for modified four-category LI-RADS (ICC, 0.68 vs 0.62, respectively; P = .03) and for dichotomized malignancy (ICC, 0.63 vs 0.53, respectively; P = .005), but not for LR-5 (P = .14) or LR-M (P = .94). Conclusion There was moderate agreement for LI-RADS version 2018 overall. For some comparisons, research-versus-research reader agreement was higher than research-versus-clinical reader agreement, indicating differences between the clinical and research environments that warrant further study. © RSNA, 2023 Supplemental material is available for this article. See also the editorials by Johnson and Galgano and Smith in this issue.
- 1 June 2023
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 307 (5) , e222855
A Multicenter Assessment of Interreader Reliability of LI-RADS Version 2018 for MRI and CT
Background Various limitations have impacted research evaluating reader agreement for Liver Imaging Reporting and Data System (LI-RADS). Purpose To assess reader agreement of LI-RADS in an international multicenter multireader setting using scrollable images. Materials and Methods This retrospective study used deidentified clinical multiphase CT and MRI and reports with at least one untreated observation from six institutions and three countries; only qualifying examinations were submitted. Examination dates were October 2017 to August 2018 at the coordinating center. One untreated observation per examination was randomly selected using observation identifiers, and its clinically assigned features were extracted from the report. The corresponding LI-RADS version 2018 category was computed as a rescored clinical read. Each examination was randomly assigned to two of 43 research readers who independently scored the observation. Agreement for an ordinal modified four-category LI-RADS scale (LR-1, definitely benign; LR-2, probably benign; LR-3, intermediate probability of malignancy; LR-4, probably hepatocellular carcinoma [HCC]; LR-5, definitely HCC; LR-M, probably malignant but not HCC specific; and LR-TIV, tumor in vein) was computed using intraclass correlation coefficients (ICCs). Agreement was also computed for dichotomized malignancy (LR-4, LR-5, LR-M, and LR-TIV), LR-5, and LR-M. Agreement was compared between research-versus-research reads and research-versus-clinical reads. Results The study population consisted of 484 patients (mean age, 62 years ± 10 [SD]; 156 women; 93 CT examinations, 391 MRI examinations). ICCs for ordinal LI-RADS, dichotomized malignancy, LR-5, and LR-M were 0.68 (95% CI: 0.61, 0.73), 0.63 (95% CI: 0.55, 0.70), 0.58 (95% CI: 0.50, 0.66), and 0.46 (95% CI: 0.31, 0.61) respectively. Research-versus-research reader agreement was higher than research-versus-clinical agreement for modified four-category LI-RADS (ICC, 0.68 vs 0.62, respectively; P = .03) and for dichotomized malignancy (ICC, 0.63 vs 0.53, respectively; P = .005), but not for LR-5 (P = .14) or LR-M (P = .94). Conclusion There was moderate agreement for LI-RADS version 2018 overall. For some comparisons, research-versus-research reader agreement was higher than research-versus-clinical reader agreement, indicating differences between the clinical and research environments that warrant further study. © RSNA, 2023 Supplemental material is available for this article. See also the editorials by Johnson and Galgano and Smith in this issue.
- Open Access
Evaluating treatment response following locoregional therapy for hepatocellular carcinoma: A review of the available serological and radiological tools for assessment
Hepatocellular carcinoma (HCC) is an aggressive primary malignancy of the liver and is the third most common cause of cancer-related global mortality. There has been a steady increase in treatment options for HCC in recent years, including innovations in both curative and non-curative therapies. These advances have brought new challenges and necessary improvements in strategies of disease monitoring, to allow early detection of HCC recurrence. Current serological and radiological strategies for post-treatment monitoring and prognostication and their limitations will be discussed and evaluated in this review.
Open AccessEvaluating treatment response following locoregional therapy for hepatocellular carcinoma: A review of the available serological and radiological tools for assessment
Hepatocellular carcinoma (HCC) is an aggressive primary malignancy of the liver and is the third most common cause of cancer-related global mortality. There has been a steady increase in treatment options for HCC in recent years, including innovations in both curative and non-curative therapies. These advances have brought new challenges and necessary improvements in strategies of disease monitoring, to allow early detection of HCC recurrence. Current serological and radiological strategies for post-treatment monitoring and prognostication and their limitations will be discussed and evaluated in this review.
- 1 January 2022
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 218 (1) , 188-189
The Global Reading Room: Postoperative Benign Biliary Stricture
- 1 January 2022
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 218 (1) , 188-189
The Global Reading Room: Postoperative Benign Biliary Stricture
- 1 February 2020
- Published by Elsevier in Clinical Radiology
- Vol. 75 (2) , 88-99
Imaging hepatic angiomyolipomas: key features and avoiding errors
- 1 February 2020
- Published by Elsevier in Clinical Radiology
- Vol. 75 (2) , 88-99
Imaging hepatic angiomyolipomas: key features and avoiding errors
- 5 June 2017
- Published by Elsevier in Clinical Imaging
- Vol. 45, 51-57
Upper extremity non-contrast magnetic resonance venography (MRV) compared to contrast enhanced MRV and ultrasound
- 5 June 2017
- Published by Elsevier in Clinical Imaging
- Vol. 45, 51-57
Upper extremity non-contrast magnetic resonance venography (MRV) compared to contrast enhanced MRV and ultrasound